What is TransCode Therapeutics, Inc. (RNAZ) stock price today?

TransCode Therapeutics, Inc. (RNAZ) is currently trading at $1.86, up 8.77% today.

What is RNAZ P/E ratio?

TransCode Therapeutics, Inc.'s P/E ratio is -0.03. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is RNAZ return on equity (ROE)?

TransCode Therapeutics, Inc.'s return on equity (ROE) is -58.08%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is TransCode Therapeutics, Inc.'s market cap?

TransCode Therapeutics, Inc. has a market capitalization of $1.97M.

NASDAQ · Biotechnology

TransCode Therapeutics, Inc. (RNAZ) Stock

$1.86 +8.77% NASDAQ: RNAZ Healthcare

Valuation

Metric	Value
Price	$1.86
Market Cap	$1.97M
P/E Ratio	-0.03
P/B Ratio	0.01
P/S Ratio	0.00
EPS (TTM)	$-52.59
52-Week High	$20.99
52-Week Low	$1.52
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-58.08%
ROA	-28.33%
ROCE	-23.83%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	7.33

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-6.0M	$-19.0M	$-19.0M	$-16.0M	$-28.0M
Net Profit	$-7.0M	$-18.0M	$-19.0M	$-17.0M	$-35.0M
EPS	$-648.00	$-1080.00	$-3453.53	$-47.14	$-52.59
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$23.0M	$8.0M	$5.0M	$7.0M	$162.0M
Total Liabilities	$3.0M	$4.0M	$4.0M	$9.0M	$152.0M
Cash	$21.0M	$5.0M	$3.0M	$6.0M	$18.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

TransCode Therapeutics to Host R&D Webcast on June 18, 2026 PR Newswire · Jun 8, 2026 RNAZ: Introducing RNA Therapeutics Zacks Small Cap Research · Jun 8, 2026 TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a MT Newswires · Jun 3, 2026 TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer PR Newswire · Jun 3, 2026 EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study Benzinga · Jun 3, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-5.0M	$-16.0M	$-18.0M	$-13.0M	$-20.0M
Investing Cash Flow	$-1.0M	$0	$0	$0	$0
Financing Cash Flow	$-1.0M	$0	$0	$0	$0
Net Cash Flow	$20.0M	$-16.0M	$-2.0M	$3.0M	$12.0M
Free Cash Flow	$-6.0M	$-16.0M	$-18.0M	$-13.0M	$-20.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.14
FCF Yield	-300617.33%
Quick Ratio	1.97
Interest Coverage	-5337.75
Return 1Y	-0.29%
Return 3Y	-99.99%
Return 5Y	-100.00%

Ownership

Insiders Held7.99%

Institutions Held6.85%

Institutions Float Held7.44%

Institutional Holder	Shares	Report Date
Geode Capital Management, LLC	12,740	2026-03-31
UBS Group AG	8,295	2026-03-31
Vanguard Capital Management LLC	6,545	2026-03-31
Vanguard Fiduciary Trust Co	2,982	2026-03-31
Tower Research Capital LLC (TRC)	228	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACXPAcurx Pharmaceuticals, Inc.	$1.27	+1.60%	-0.36	$5.46M	0.00%
APREAprea Therapeutics, Inc.	$0.60	+8.28%	-0.64	$7.48M	0.00%
APVOAptevo Therapeutics Inc.	$1.79	-0.56%	-0.01	$3.91M	0.00%
BOLTBolt Biotherapeutics, Inc.	$4.11	+12.60%	-0.22	$7.90M	0.00%
GLTODamora Therapeutics, Inc.	$21.58	-3.36%	-0.17	$34.47M	0.00%

About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. is led by CEO Philippe Calais, publicly traded since 2021.

TransCode Therapeutics, Inc. (RNAZ) stock trades at $1.86 with a market capitalization of $1.97M. The stock is valued at a price-to-earnings (P/E) ratio of -0.03, price-to-book of 0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.52 and $20.99, and currently trades 91.1% below its 52-week high.

On profitability, TransCode Therapeutics, Inc. generates a return on equity (ROE) of -58.08%, return on capital employed of -23.83%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides